Montelukast and Alzheimer Disease: A Comprehensive Review - Badulla, Wafa; Hussein, Weiam; AL-Heibshy, Fawaz
26,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
13 °P sammeln
  • Broschiertes Buch

Alzheimer¿s disease (AD), is considered as one of the most prominent, multifactorial, age-related neurodegenerative disease in the world. The treatments that have been developed up to now, have only an auxiliary effect & not therapeutic or curative. The real cause of AD is still being a mystery for the researchers since the first description of the disease over 100 years ago. The arena of AD hypothesis is continuously expanding, which provides a better cognition of AD and the development of new medication for reducing the symptoms & offering a better life for AD patients. Neuroinflammation is…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Alzheimer¿s disease (AD), is considered as one of the most prominent, multifactorial, age-related neurodegenerative disease in the world. The treatments that have been developed up to now, have only an auxiliary effect & not therapeutic or curative. The real cause of AD is still being a mystery for the researchers since the first description of the disease over 100 years ago. The arena of AD hypothesis is continuously expanding, which provides a better cognition of AD and the development of new medication for reducing the symptoms & offering a better life for AD patients. Neuroinflammation is considered as one underlining cause of brain aging & neurodegenerative diseases. The cysteinyl leukotrienes (CycLTs) have an important role in maintaining the physiological conditions & in the development of some pathological conditions. Lately, there have been several researches that elucidated the role of CycLTs for several neurological perplexities accountable for the progress of AD. Herein, the effects of CycLTs in the development of AD will be summarized & highlight the effectiveness of CycLTs inhibitors, especially Montelukast Sodium (MON) in the treatment of AD in the near future.
Autorenporträt
Wafa F. S. Badulla ha completato il suo dottorato di ricerca nel 2017 presso l'Università di Anadolu, Istituto di Scienze della Salute. Ora lavora all'Università di Aden, Facoltà di Farmacia, come assistente professore. Ha lavorato in precedenza sull'analisi di Montelukast ed Escitalopram e si è interessata ai farmaci e alle malattie del SNC.